We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0A4Y market cap is 0. The company's latest EPS is USD -0.5930 and P/E is -3.04.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 140k | 163k | 135k | 141k | 202k |
| Operating Income | -12.44M | -15.02M | -17.06M | -19.92M | -31.92M |
| Net Income | -9.53M | -14.4M | -19.13M | -19.45M | -28.96M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 20.22M | 64.58M | 57.7M | 40.49M | 19.38M |
| Total Liabilities | 7.31M | 3.29M | 820k | 2.02M | 9.15M |
| Total Equity | 12.91M | 61.29M | 56.88M | 38.47M | 10.23M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -9.07M | -10.37M | -13.97M | -16.11M | -21.27M |
| Investing | -6.15M | -9.16M | -631k | 10.99M | -832k |
| Financing | 16.39M | 56.56M | 8.19M | 80k | 485k |
| Market Cap | 0 |
| Price to Earnings Ratio | -3.04 |
| Price to Sales Ratio | 439.02 |
| Price to Cash Ratio | 16.16 |
| Price to Book Ratio | 8.59 |
| Dividend Yield | - |
| Shares Outstanding | 48.84M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Aim Immunotech Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.aimimmuno.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
